CellSource Co (TSE:4880) Other Financing: 円177 Mil (TTM As of Apr. 2026)


TSE:4880 CellSource Co Ltd TSE:4880
69 GF Score
Price 円347.00
GF Value 円781.31
Valuation Significantly Undervalued
! 6 Warning Signs
View Full Analysis

What is CellSource Co Other Financing?

CellSource Co TSE:4880 +8.78% 69 Other Financing is 円177 Mil as of Apr. 2026. GuruFocus rates TSE:4880 with a GF Score™ of 69/100 and a GF Value™ of 円781.31 (Significantly Undervalued). The stock has 6 warning signs investors should review.

CellSource Co's Other Financing for the six months ended in Apr. 2026 was 円-3 Mil.

CellSource Co's Other Financing for the trailing twelve months (TTM) ended in Apr. 2026 was 円177 Mil.

CellSource Co Other Financing Historical Data

* Premium members only.

The historical data trend for CellSource Co's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CellSource Co Other Financing Chart

CellSource Co Annual Data
Trend Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
Other Financing
Get a 7-Day Free Trial Premium Member Only 0.80 0.25 -6.00 -19.49 -0.00

CellSource Co Semi-Annual Data
Oct17 Oct18 Oct19 Apr20 Oct20 Apr21 Oct21 Apr22 Oct22 Apr23 Oct23 Apr24 Oct24 Apr25 Oct25 Apr26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -19.49 0.00 -0.00 180.30 -3.00
TSE:4880
69GF Score
CellSource Co Ltd TSE:4880
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CellSource Co Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Apr. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円177 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of 円177 Mil mean?
CellSource Co (TSE:4880) has a Other Financing of 円177 Mil as of Apr. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for CellSource Co and its competitors.
Is CellSource Co's Other Financing too high?
CellSource Co's current Other Financing is 円177 Mil. Overall, CellSource Co has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellSource Co's Other Financing compare to VRTX and REGN?
CellSource Co's Other Financing of 円177 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for CellSource Co and its competitors. CellSource Co's current Other Financing is 円177 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellSource Co stock overvalued right now?
Based on GuruFocus' analysis, CellSource Co (TSE:4880) is currently considered Significantly Undervalued. The stock's GF Value™ is 円781.31, compared to a current price of 円347.00 — trading 55.6% below its estimated fair value. The current Other Financing is 円177 Mil. CellSource Co's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For CellSource Co (TSE:4880), the current Other Financing is 円177 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CellSource Co (TSE:4880) Overvalued in 2026?

Based on GuruFocus' analysis, CellSource Co stock appears to be undervalued. The current stock price of 円347.00 is trading 55.6% below its estimated GF Value™ of 円781.31. GuruFocus considers CellSource Co to be Significantly Undervalued.

Key valuation signals for TSE:4880:

  • Other Financing: 円177 Mil
  • GF Value™: 円781.31 vs. price of 円347.00 (55.6% below fair value)
  • GF Score™: 69/100 with 6 warning signs

No single metric tells the full story. See the TSE:4880 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CellSource Co Business Description

Address Shibuya Mitake Building, 2nd Floor, 1-19-5 Shibuya, Shibuya-ku, Tokyo, JPN, 150-0002
CellSource Co Ltd is engaged in contract manufacturing of fat-and blood-derived organizations and cells from medical institutions, provision of legal support to medical institutions in the regenerative medicine business. The company is also involved in sales of medical devices, and sales of own-brand cosmetics in the consumer business.
69GF Score

Get the complete analysis for TSE:4880

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円347.00
Price
円781.31
GF Value